Literature DB >> 15114269

Diagnosis of migrainous vertigo: validity of a structured interview.

Dawn A Marcus1, Cindy Kapelewski, Thomas E Rudy, Rolf G Jacob, Joseph M Furman.   

Abstract

BACKGROUND: Migraine and vestibular symptoms are co-morbid. Migraine is increasingly recognized as a cause of benign, recurrent vertigo. Although the International Headache Society does not currently include the diagnosis of migrainous vertigo, specific criteria have been proposed and utilized in clinical trials. MATERIAL/
METHODS: Seventeen adult migraineurs were separately screened for the diagnosis of migrainous vertigo using a standardized structured interview for migrainous vertigo (SIM-V) and a clinical evaluation by an experienced neurotologist. The SIM-V was administered by a nurse who read and recorded subject responses, obtaining no additional information for the diagnosis of migrainous vertigo. Comparison of diagnoses between clinician and SIM-V was made using Cohen's kappa reliability testing. Subjects were asked to return for a second interview by the same nurse using the SIM-V, at least 2 weeks after the initial assessment. Testing stability was evaluated by comparing diagnoses obtained with each SIM-V administration.
RESULTS: Cohen's kappa demonstrated excellent test validity (kappa=0.75). Fourteen subjects returned for repeat testing, with excellent retest stability (kappa=0.85). The additional three subjects could not be relocated or were not interested in attending a retest appointment.
CONCLUSIONS: The SIM-V is an easy-to-administer screening tool for the diagnosis of migrainous vertigo. Diagnostic comparison to a standard clinical assessment shows good test validity. Retest stability was also demonstrated. The SIM-V may be a useful screening tool for migraineurs with an additional complaint of dizziness.

Entities:  

Mesh:

Year:  2004        PMID: 15114269

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  5 in total

1.  Locus for familial migrainous vertigo disease maps to chromosome 5q35.

Authors:  Fayez Bahmad; Steven R DePalma; Saumil N Merchant; Roberta L Bezerra; Carlos A Oliveira; Christine E Seidman; Jonathan G Seidman
Journal:  Ann Otol Rhinol Laryngol       Date:  2009-09       Impact factor: 1.547

2.  Rizatriptan reduces vestibular-induced motion sickness in migraineurs.

Authors:  Joseph M Furman; Dawn A Marcus; Carey D Balaban
Journal:  J Headache Pain       Date:  2010-09-23       Impact factor: 7.277

3.  A pilot study of rizatriptan and visually-induced motion sickness in migraineurs.

Authors:  Joseph M Furman; Dawn A Marcus
Journal:  Int J Med Sci       Date:  2009-08-06       Impact factor: 3.738

4.  Results and lessons learnt from a randomized controlled trial: prophylactic treatment of vestibular migraine with metoprolol (PROVEMIG).

Authors:  Otmar Bayer; Christine Adrion; Amani Al Tawil; Ulrich Mansmann; Michael Strupp
Journal:  Trials       Date:  2019-12-30       Impact factor: 2.279

Review 5.  Migraine associated with auditory-vestibular dysfunction.

Authors:  Renato Cal; Fayez Bahmad
Journal:  Braz J Otorhinolaryngol       Date:  2008 Jul-Aug
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.